To maximize the potential of innovative therapies in the Chinese market, it’s important to have a holistic view of the full range of options and levers, prioritize and sequence the ones with the highest impacts, and develop an integrated strategy tailored to address the country’s unmet needs.
Encounters with healthcare providers (HCPs) requires diligent preparation. Beyond understanding the value of the therapies you're offering, all touchpoints and conversations are of the highest importance - through sharing research, new ideas, and how you can support HCPs, you gain valuable, relevant insights that inform your relationship with HCPs and help them blossom.
Amy Butcher evaluates the current treatment options for prostate cancer and the looks to the future as clinical outcomes evolve.
In this video Akeel Williams, VP of Strategy and Operations, Manufacturer Solutions, explains how GoodRx uses data to continuously improve its platform for patients and providers.
Companies recognize that their success with digital starts with accurate customer data, but many struggle to manage the overwhelming volume of different data types from hundreds of sources.
Here’s how pharma businesses can speed the handling of adverse events, reduce costs, improve patient safety and spur growth through pharmacovigilance automation.
Lofaso discusses strategies that biotech companies can take once its time to make the big push.
The era of big pharma as product-first companies must end, as services become the larger priority.
As social media continues to influence healthcare communication, it presents both challenges and opportunities for the pharmaceutical industry. In this interview, Jennifer Harakal of Canopy Life Sciences discusses balancing compliance with effective digital engagement to build trust and facilitate meaningful healthcare conversations.
Pharma companies are struggling to maintain a high level of cybersecurity amidst the pandemic.
If you wish for your team to be diligent, innovative, and collaborative, you must first exhibit these traits yourself
Pharma companies may benefit from meeting challenges and embracing small molecule drug discovery.
Conferences, congresses, and the digital discussions kicked off by those events create a halo effect that amplifies scientific information more so than other scientific activities.
Traditional approaches to HCP segmentation are no longer sufficient. The challenge now is to maintain personalization at scale while managing large territories and diverse customer bases.
How life sciences companies can design an effective operating model for DOL engagements.
Utilizing natural language processing technologies to improve search capabilities and advance the development of therapies.
How pharma medical affairs and commercial teams are synchronizing their capabilities to boost omnichannel marketing strategies and better understand customer engagement needs.
In early phase trials innovative designs offer potential for improvements in efficiency and decision-making.
The top changes necessary in planning and designing pharma market access plans, including a revamp of the payer-value equation at pivotal points in the product life cycle.
This white paper describes how digitizing medicines can drive patient engagement, reduce non-adherence, and enhance supply chain visibility.
Pharma companies should review their commission-based compensation arrangements with independent contractors to address enforcement risk under the Anti-Kickback Statute, in light of recent Department of Justice enforcement.
Brand positioning that targets HCPs is often irrelevant to the payer mindset. Fortunately, market access teams have an option, writes Ed Shankman.
Measuring the relationship between a product’s reimbursement position and performance begins with gathering key data points for as many products as possible.
In today’s fragmented commercial environment, navigating a more complex set of challenges while adapting new approaches to product launch is critical for biopharma brand teams.
Overcoming persistent barriers to health equity in oncology trials will require innovation and cooperation.